Third dose of Pfizer-BioNTech vaccine, incidence of Covid infection, hospitalization, death

JAMA Network

About The Study: This study of 18,000 residents of long-term care facilities in Israel found that those who had received a third dose (first booster dose) of the Pfizer-BioNTech vaccine had a significantly lower risk for overall SARS-CoV-2 infection, COVID-19 hospitalizations, severe disease and related deaths during the Delta variant surge compared with those who received two doses five months or longer prior to the potential exposure.

Authors: Khitam Muhsen, Ph.D., of Tel Aviv University, is the corresponding author.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamanetworkopen.2022.19940)

/Public Release. This material from the originating organization/author(s) may be of a point-in-time nature, edited for clarity, style and length. The views and opinions expressed are those of the author(s).View in full here.